You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: Translational Sciences Inc.            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Modeling Disease in Swine by Transplantation of Gene Targeted Germ Cells

    SBC: Recombinetics, Inc.            Topic: 400

    PROJECT SUMMARY Swine are important in biomedical research for the study of human diseases that are poorly recapitulated by rodent speciesfor the development and testing of preclinical therapeutics in humanized disease models and as potential sources of xenogeneic or allogeneic organs and tissuesHoweverthe creation and propagation of biomedical swine is plagued by inefficiencies related to animal ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS INC.            Topic: 102

    ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

    SBC: Vyriad, Inc.            Topic: 102

    PROJECT SUMMARY ABSTRACTBladder cancer is a leading cause of death in the US and the most expensive cancer to treatDespite thisthere has been only one new bladder cancer therapythe checkpoint inhibitor atezoluzimabapproved in the pastyearsOncolytic virusesviruses that selectively infect and kill cancer cellsare a potent new class of immunotherapy that mediate anticancer activity by direct virus in ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Infrared Eyes(iREyes)

    SBC: Korosensor.Com, Inc.            Topic: 200

    Infrared Eyes Abstract Eden Medical, Inc. is pleased to submit this Phase 2 SBIR proposal to develop the “Infrared Eyes” (iREyes) imager system, an affordable and powerful mobile health (mHealth) tool for healthcare. The hand-held iREyes system will acquire both thermal and visible spectrum imagery to quantify healing via thermal indexing methodology. The iREyes will offer a user-friendly prod ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Interactive Digital Media to Support Children's Learning about Tobacco and the Human Body: "Dusty the Dragon"

    SBC: MOAI TECHNOLOGIES, LLC            Topic: 500

    Abstract This SBIR Phase II project will develop an innovative STEM online game that combines biology education about parts of the human body while also teaching about the bad health effects on the body of smoking and other tobacco useThe target audience is students in gradeswhich lines up with health curriculum coverage of these topics in most statesThe entertaining and challenging aspects of the ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government